Apellis Pharmaceuticals's total assets for Q4 2024 were $885.05M, a decrease of -1.86% from the previous quarter. APLS total liabilities were $656.51M for the fiscal quarter, a -1.24% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.